Home Health

FDA provides panel to evaluate diagnostic tests available for COVID-19

The U.S. Food and Drug Administration (FDA) is providing a SARS-COV-2 reference panel for the evaluation of diagnostic tests for COVID-19. The panels safeguard the quality of the tests and validation of new assay. They also test the calibration and monitoring of assay performance.

The FDA panel is available to commercial and laboratory developers who interact with the FDA through the pre-emergency use authorization (EUA) process.

Related link: For more information on the SARS-COV-2 reference panel, visit: https://bit.ly/3cjoWf0.